CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0600

RAD140

Filed under Oral Tablets. The bureau holds 127 laboratory returns for this compound from 40 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

40 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
HomopeptideCASE #VI-2026-0760 A 6 10.0 9.9 10.0 21 May 2026 21 May 2026
WuXi TIDESCASE #VI-2026-0335 A 5 10.0 9.9 10.0 11 Dec 2025 22 Jul 2026
QYAOBIOCASE #VI-2026-0861 A 4 10.0 9.9 10.0 19 Nov 2025 22 Jun 2026
Kerui PeptidesCASE #VI-2026-0626 A 4 10.0 9.9 10.0 21 Feb 2026 1 May 2026
GenScript PeptidesCASE #VI-2026-0860 A 4 10.0 10.0 10.0 8 Feb 2026 18 Aug 2026
Sangon BioCASE #VI-2026-0671 A 3 10.0 10.0 10.0 11 Dec 2025 6 Jul 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 3 10.0 9.9 10.0 4 Feb 2026 7 Jun 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 3 10.0 9.9 10.0 3 Jun 2026 23 Jul 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 3 10.0 9.9 10.0 28 May 2026 16 Jun 2026
Sigma-AldrichCASE #VI-2026-0829 A 3 10.0 10.0 10.0 19 Jan 2026 19 Apr 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 3 10.0 9.9 10.0 2 Jul 2026 10 Aug 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 2 10.0 10.0 10.0 19 Mar 2026 15 May 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 2 10.0 10.0 10.0 13 Jan 2026 19 Jun 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 2 10.0 10.0 10.0 12 Feb 2026 8 Apr 2026
Hunan GoodPeptides Biotech CoCASE #VI-2026-0370 X 1 10.0 10.0 10.0 9 Jun 2025 9 Jun 2025
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 6 9.9 9.9 10.0 14 Nov 2025 16 Apr 2026
AmbioPharmCASE #VI-2026-0177 A 4 9.9 9.9 10.0 11 Jan 2026 20 Aug 2026
JEEP PeptidesCASE #VI-2026-0457 A 3 9.9 9.9 10.0 23 Mar 2026 6 Jun 2026
BachemCASE #VI-2026-0314 A 3 9.9 9.9 9.9 6 May 2026 19 Jun 2026
SinoPepCASE #VI-2026-0387 A 3 9.9 9.9 10.0 21 Jun 2026 13 Jul 2026
Hubei JianxiangCASE #VI-2026-0048 A 2 9.9 9.9 10.0 15 Apr 2026 7 Jun 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 2 9.9 9.9 10.0 27 Apr 2026 8 Jul 2026
PolyPeptide GroupCASE #VI-2026-0143 A 2 9.9 9.9 9.9 14 Feb 2026 17 Apr 2026
AsymchemCASE #VI-2026-0091 A 2 9.9 9.9 9.9 24 Jan 2026 15 Feb 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 3 9.5 8.6 10.0 24 May 2026 24 May 2026
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 6 8.6 7.3 10.0 21 May 2026 21 May 2026
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 8 8.5 7.8 9.7 24 May 2026 24 May 2026
Glbiochem (Shanghai)CASE #VI-2026-0704 A 8 8.2 7.1 9.2 25 May 2026 25 May 2026
CellupepCASE #VI-2026-0888 X 1 8.2 8.2 8.2 24 Apr 2025 24 Apr 2025
EHZ PeptidesCASE #VI-2026-0296 C 2 8.1 7.8 8.3 6 May 2025 23 May 2026
Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 X 1 8.1 8.1 8.1 7 May 2025 7 May 2025
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 4 7.7 7.1 9.0 23 May 2026 23 May 2026
Oasis PeptidesCASE #VI-2026-0404 X 1 7.6 7.6 7.6 8 Jul 2025 8 Jul 2025
Pure Tested PeptidesCASE #VI-2026-0225 X 1 7.5 7.5 7.5 14 Jan 2025 14 Jan 2025
Precision Peptide CoCASE #VI-2026-0559 X 2 7.2 6.7 7.6 3 Jun 2025 24 May 2026
Pura PeptidesCASE #VI-2026-0307 X 1 7.1 7.1 7.1 21 May 2025 21 May 2025
HXNetCASE #VI-2026-0061 X 8 6.8 4.9 9.4 17 Dec 2024 19 Jan 2026
Zenith Jove Peptide ZJCASE #VI-2026-0570 X 2 6.1 5.9 6.2 14 Jan 2025 24 May 2026
Heman Peptide HMCASE #VI-2026-0089 X 1 4.6 4.6 4.6 6 May 2025 6 May 2025
Suaway Lab ResearchCASE #VI-2026-0488 X 3 2.8 2.1 3.3 16 Mar 2025 25 May 2026

Open any subject to view the batch-level evidence for RAD140 alone.